The effect of Dr Allen's Device and Thermobalancing Therapy on erectile dysfunction in men with chronic prostate diseases

Investigation of the effect of Thermobalancing therapy and Dr Allen's Device for Prostate Treatment on erectile dysfunction, prostate volume, and health-related quality of life in men with chronic prostatitis/chronic pelvic pain syndrome and benign prostate enlargement

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN54235113

Enrollment

100

Registered

2023-01-09

Start date

2023-01-12

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment for erectile dysfunction in patients with benign prostate enlargement or chronic prostatitis/chronic pelvic pain syndrome Urological and Genital Diseases

Interventions

The purpose of this clinical trial is to investigate the effect of the out-of-hospital treatment with Thermobalancing therapy and Dr Allen's Device for Prostate Treatment on erectile dysfunction, the

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Aged between 40 and 55 with ED due to CP/CPPS or BPH

Exclusion criteria

Exclusion criteria: 1. Previous prostate surgeries 2. Infectious diseases 3. Severe comorbidities, such as cancer, heart failure, and end-stage chronic diseases 4. Cognitive impairment 5. Mental illness

Design outcomes

Primary

Measure	Time frame
The following outcomes will be assessed three times in total, before, during and at the end of the treatment period: 1. Severity of erectile dysfunction measured using the International Index of Erectile Function (IIEF-5) Questionnaire 2. Volume of the prostate gland measured using ultrasound 3. Severity of urinary symptoms measured using the AUA Symptom Score Questionnaire	—

Secondary

Measure	Time frame
The following outcomes will be assessed three times in total, before, during and at the end of the treatment period: 1. Health-related quality of life (HRQoL) measured using the Short Form Survey Instrument (SF-36) 2. Serum levels of prostate-specific antigen, total testosterone, and 17ß-estradiol (E2) measured using blood samples and standard techniques	—

Countries

Pakistan

Contacts

Public ContactAriana Adjani

ariana.adjani@finetreatment.com+44 (0)7958878300

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026